Skip to main content

Table 5 Response in ascites

From: A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

Groups N Disappeared
(N) (%)
Decreased
(N) (%)
No change
(N) (%)
Increased
(N) (%)
NE
(N) (%)
P value*
All patients with ascites 40 3 (7.5) 11 (27.5) 12 (30) 12 (30) 2 (5) 0.88
Small to moderate ascites 26 3 (12) 6 (23) 9 (35) 8 (31) 0  
Massive ascites 14 0 5 (36) 3 (21) 4 (29) 2 (14)  
  1. Disappeard: disappearance of ascites
  2. Decreased: from moderate to small, from massive to moderate or small
  3. Increased: from small to moderate or massive, from moderate to massive
  4. *Comparison of response between 2 groups